Thompson Davis & Co’s Biogen BIIB Stock Holding History

Thompson Davis & Co’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-152	Closed	-$48K	–	715
2017 Q3	$48K	Buy	152 +13	+9%	+$3.85K	0.09%	240
2017 Q2	$38K	Hold	139	–	–	0.06%	271
2017 Q1	$38K	Buy	139 +2	+1%	+$565	0.05%	294
2016 Q4	$39K	Buy	137 +14	+11%	+$4.15K	0.06%	281
2016 Q3	$39K	Hold	123	–	–	0.07%	290
2016 Q2	$30K	Buy	123 +8	+7%	+$2.11K	0.05%	338
2016 Q1	$30K	Sell	115 -10	-8%	-$2.64K	0.04%	330
2015 Q4	$38K	Hold	125	–	–	0.05%	301
2015 Q3	$36K	Sell	125 -308	-71%	-$102K	0.05%	317
2015 Q2	$175K	Buy	433 +285	+193%	+$114K	0.2%	107
2015 Q1	$62K	Sell	148 -269	-65%	-$106K	0.07%	249
2014 Q4	$142K	Sell	417 -6	-1%	-$1.94K	0.16%	129
2014 Q3	$140K	Buy	+423	New	+$139K	0.18%	118
2014 Q2	–	Sell	-21	Closed	-$6K	–	766
2014 Q1	$6K	Sell	21 -355	-94%	-$113K	0.01%	595
2013 Q4	$105K	Buy	+376	New	+$97.3K	0.16%	146

Other funds holding BIIB

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Thompson Davis & Co's BIIB Position: Q4 2017 in Review

Thompson Davis & Co sold out of Biogen (BIIB) in Q4 2017, closing a stake of 152 shares — an estimated $48K sold.

Thompson Davis & Co first reported a position in BIIB in Q4 2013 and held it in 15 quarters. The position peaked at $175K in Q2 2015. 1,123 funds tracked by Wall St. Rank hold BIIB as of Q4 2017.

Thompson Davis & Co reported no remaining Biogen position as of Q4 2017 after selling out during the quarter.
Thompson Davis & Co sold 152 Biogen shares in Q4 2017, an estimated $48K.
Thompson Davis & Co first reported a position in Biogen in Q4 2013 and held it in 15 quarters.
Thompson Davis & Co's Biogen position peaked at $175K in Q2 2015.
1,123 funds tracked by Wall St. Rank held Biogen as of Q4 2017.

Based on Thompson Davis & Co's 13F filing for Q4 2017, filed 5 Feb 2018.